Regulatory & Legal

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

The EU's landmark decision to ease rules on New Genomic Techniques opens a multi-billion dollar market, and ag-tech pioneer Cibus is ready to cash in.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Salesforce's AI agents are set to overhaul the USDOT, tackling legacy tech to speed up grants, enhance safety, and redefine federal efficiency.

A new solar-plus-storage project in Sicily showcases how tailored energy solutions can boost industrial autonomy, cut costs, and withstand harsh climates.

Bluerock Acquisition Corp. has raised $150 million. With a sector-agnostic mandate, could this new capital pool target the mining industry?

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Vision Fortune Finance Institute unveils a powerful new data engine for its Nexus AI, aiming to revolutionize financial research by taming data overload.

On Human Rights Day, Ottawa touts global leadership, but a chasm grows between its international promises and the stagnant progress on justice at home.